Developing rational combination cancer therapy requires understanding how cancer cells adapt to initial treatments.

“So my talking point was we need to find in cancer a as many AZTs as we need as the initial foot in the door. We know we're going to see resistance in this much more complex entity that is a human cell that's gone rogue versus relatively simple virus. but it's when we poke it with the AZT equivalents, we're going to learn about how it is that it tries to adapt. And that's going to allow us to develop rational combination therapy exactly the way the HIV field does.”